Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.

Get the latest S&P 500 healthcare stock winners & losers, major earnings beats, profit forecasts, and legal news for key companies.

When it comes to putting cash into stocks that you can buy and hold for the long run, and could outperform for years as part of a well-diversified portfolio, here are two top stocks to consider now.

Berkshire reported $13.485 billion in operating profit from its wholly owned businesses in the third quarter, a 34% increase ...

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless”.

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Scripps Research in La Jolla announce a new clinical trial that will assess the effectiveness of using drugs approved for diabetes treatment and weight loss to treat long COVID-19, the debilitating ...

The U.S. stock market sank from record heights as Wall Street sifted through mixed developments on everything from the ...

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

Eli Lilly has once again delivered extraordinary financial results, powered by its highly successful diabetes and obesity treatments. The pharmaceutical giant's third-quarter performance has left ...